Rhumbline Advisers Opti Nose, Inc. Transaction History

Rhumbline Advisers

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$0.82 - $1.44 $69,725 - $122,444	-85,031 Reduced 90.38%	9,054 $9,000
Q1 2024 May 09, 2024	BUY	$1.17 - $1.94 $3,287 - $5,451	2,810 Added 3.08%	94,085 $137,000
Q4 2023 Feb 08, 2024	BUY	$1.02 - $1.47 $25,512 - $36,767	25,012 Added 37.75%	91,275 $117,000
Q3 2023 Nov 09, 2023	BUY	$0.93 - $1.38 $3,613 - $5,362	3,886 Added 6.23%	66,263 $81,000
Q2 2023 Aug 08, 2023	BUY	$1.11 - $2.05 $69,238 - $127,872	62,377 New	62,377 $76,000
Q2 2021 Aug 05, 2021	SELL	$2.91 - $3.83 $99,193 - $130,553	-34,087 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$3.2 - $4.98 $9,696 - $15,089	3,030 Added 9.76%	34,087 $141,000
Q3 2020 Nov 12, 2020	SELL	$3.69 - $7.09 $16,199 - $31,125	-4,390 Reduced 12.38%	31,057 $121,000
Q2 2020 Aug 13, 2020	BUY	$3.58 - $7.44 $20,108 - $41,790	5,617 Added 18.83%	35,447 $264,000
Q1 2020 May 06, 2020	BUY	$3.49 - $9.2 $2,774 - $7,313	795 Added 2.74%	29,830 $134,000
Q4 2019 Feb 05, 2020	BUY	$6.27 - $11.41 $1,680 - $3,057	268 Added 0.93%	29,035 $268,000
Q3 2019 Oct 23, 2019	SELL	$4.75 - $8.38 $878 - $1,550	-185 Reduced 0.64%	28,767 $201,000
Q2 2019 Aug 14, 2019	BUY	$6.4 - $10.94 $32,985 - $56,384	5,154 Added 21.66%	28,952 $205,000
Q1 2019 May 01, 2019	BUY	$6.1 - $10.3 $542 - $916	89 Added 0.38%	23,798 $245,000
Q4 2018 Jan 31, 2019	BUY	$5.84 - $11.92 $51,088 - $104,276	8,748 Added 58.47%	23,709 $147,000
Q3 2018 Nov 07, 2018	BUY	$12.43 - $29.76 $621 - $1,488	50 Added 0.34%	14,961 $186,000
Q2 2018 Aug 06, 2018	BUY	$18.75 - $28.46 $279,581 - $424,367	14,911 New	14,911 $417,000

88.3M

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $42.5M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.